Synhale Therapeutics

Synhale Therapeutics is a biotechnology company dedicated to developing inhaled treatments for respiratory infections and chronic lung diseases. The company was founded as a spin-out from the University of North Carolina at Chapel Hill, utilizing research from the Marsico Lung Institute. Synhale's primary focus is on inhaled polyanionic therapies that can neutralize respiratory viruses and improve airway clearance. Their lead candidate, SYN-001, is designed to treat COVID-19 by blocking viral entry into lung cells. Beyond viral infections, the company explores applications for its delivery platform in conditions like cystic fibrosis and COPD. Synhale aims to transform respiratory care by providing localized, high-concentration therapy directly to the lungs.